ArticleJournal of cancer research and clinical oncology2014

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.

Daria Zdzalik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.